13F Holdings
中文EN

PRGO PERRIGO Co plc

Pharmaceutical Preparations · NYSE · SEC CIK 1585364 · Fiscal year ends 12/31

Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.5%
TTM net income YoY-3,316.4%
TTM EPS YoY-3,351.4%
Revenue 3-yr CAGR-4.2%
Net income 3-yr CAGR—

Margins

Gross margin32.3%
Operating margin-39.4%
Net margin-43.3%
FCF margin4.1%
EBITDA margin-33.6%

Returns

ROE-51.4%
ROA-20.1%
ROIC (approx.)-19.7%
Asset turnover0.47x

Leverage & solvency

Liabilities / assets67.4%
Debt / equity1.35x
Current ratio2.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.14x
Accruals ratio-22.9%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$4.25B$4.37B$4.66B$4.45B$4.14B
Cost of revenue$2.76B$2.83B$2.98B$3.00B$2.72B
Gross profit$1.49B$1.54B$1.68B$1.46B$1.42B
R&D expense$95.40M$112.20M$122.50M$123.10M$122.00M
SG&A expense$435.90M$468.00M$522.30M$512.30M$482.00M
Operating income-$1.12B$112.90M$151.90M$78.90M$410.40M
Pretax income-$1.30B-$80.70M-$8.30M-$139.10M$258.70M
Income tax$104.40M$80.00M-$3.90M-$8.20M$389.60M
Net income-$1.43B-$171.80M-$12.70M-$140.60M-$68.90M
EBITDA-$784.70M$438.80M$511.40M$417.50M$722.60M
EPS (basic)-10.29-1.25-0.09-1.04-0.52
EPS (diluted)-10.29-1.25-0.09-1.04-0.52
Dividends declared per share1.161.101.091.040.96
Weighted avg. shares (diluted)138.50M137.40M135.30M134.50M133.60M
Banking
Net interest income——-$173.80M-$156.00M-$125.00M
Balance sheet
Cash & equivalents$531.60M$558.80M$751.30M$600.70M$1.86B
Receivables$612.80M$642.30M$739.60M$697.10M$652.90M
Inventory$1.15B$1.08B$1.14B$1.15B$1.02B
Current assets$2.80B$2.48B$2.83B$2.72B$3.86B
PP&E, net$898.70M$917.80M$916.40M$926.30M$864.10M
Goodwill$2.05B$3.32B$3.53B$3.49B$3.00B
Intangibles$4.76B$4.50B$5.00B$5.01B$3.68B
Total assets$8.54B$9.65B$10.81B$11.02B$10.43B
Current liabilities$1.01B$1.04B$1.59B$1.11B$1.59B
Short-term debt$36.60M$36.40M$440.60M$36.20M$603.80M
Long-term debt$3.60B$3.58B$3.63B$4.07B$2.92B
Total debt$3.64B$3.62B$4.07B$4.11B$3.52B
Total liabilities$5.60B$5.33B$6.04B$6.18B$5.27B
Shareholders' equity$2.94B$4.32B$4.77B$4.84B$5.15B
Net debt$3.11B$3.06B$3.32B$3.51B$1.66B
Shares outstanding137.60M136.50M135.50M134.70M—
Cash flow statement
Operating cash flow$238.50M$362.90M$405.50M$307.30M$156.30M
Capital expenditure$93.40M$118.30M$101.70M$96.40M$152.10M
Free cash flow$145.10M$244.60M$303.80M$210.90M$4.20M
Investing cash flow-$75.40M$78.80M-$77.50M-$1.96B$1.28B
Financing cash flow-$220.50M-$611.00M-$187.20M$421.60M-$178.70M
Depreciation & amortization$337.50M$325.90M$359.50M$338.60M$312.20M
Stock-based compensation$54.60M$64.40M$68.80M$54.90M$60.10M
Dividends paid$159.30M$152.50M$149.70M$142.40M$129.60M
Share buybacks———$0$0

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.